Predict Antidepressant Responsiveness Using Pharmacogenomics

Samsung Medical Center1 site in 1 country1,000 target enrollmentFebruary 2003

ConditionsDepression Depressive Symptoms

InterventionsSSRI treated group non-SSRI treated group

DrugsSSRI treated group non-SSRI treated group

Overview

Phase: Not Applicable
Intervention: SSRI treated group
Conditions: Depression
Sponsor: Samsung Medical Center
Enrollment: 1000
Locations: 1
Primary Endpoint: Presences of each individual symptom of depression at 1,2,4,6,12 weeks
Last Updated: 10 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to determine whether genetic information associated with individual depressive symptoms.

Detailed Description

The primary hypothesis is that the variations of the candidate genes are associated with individual symptoms in patients with depression. The Second hypothesis is that patients with the associated genetic variation suffer longer from the associated symptom than the patients without the associated genetic variation.

Registry

clinicaltrials.gov

Start Date

February 2003

End Date

December 2018

Last Updated

10 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Samsung Medical Center

Responsible Party

Principal Investigator

Doh Kwan Kim

M.D., Ph.D.

Samsung Medical Center

Eligibility Criteria

Inclusion Criteria

•Eligible patients were enrolled in the clinical trials program of hte Samsung Medical Center Geropsychiatry and Affective Disorder Clinics(Seoul, Korea). They received a semistructured diagnostic interview, the Samsung Psychiatric Evaluation Schedule. The affective disorder section of the Samsung Psychiatric Evaluation Schedule uses the Korean version of the structured clinical interview for the diagnostic and statistical manual of mental disorders, Fourth edition.
•interview with one more patient's family member for objective diagnosis and final diagnosis decision by agreements of two more psychiatric physicians

Exclusion Criteria

•received psychotropic medication within 2 weeks of the study or fluoxetine within 4 weeks
•potential study participants for pregnancy, significant medical conditions, abnormal laboratory baseline values, unstable psychiatric features(eg.suicidal), history of alcohol of drug dependence, seizures, head trauma with loss of consciousness, neurological illness, or concomitant Axis I psychiatric disorder.